Pre-Open Stock Movers 09/13: (ITMR) (LPTX) (BLU) Higher; (MDXG) (FAMI) (VALN) Lower (more...)

Today's Pre-Open Stock Movers:

MiMedx Group, Inc. (Nasdaq: MDXG) 53% LOWER; announced top-line results from two late-stage musculoskeletal clinical trials of the Companys micronized dehydrated Human Amnion Chorion Membrane (mdHACM): a Phase 2B clinical trial for the treatment of Knee Osteoarthritis (KOA) and a Phase 3 clinical trial for the treatment of Plantar Fasciitis (PF).

Farmmi, Inc. (NASDAQ: FAMI) 49% LOWER; announced the pricing of an underwritten public offering of ordinary shares and pre-funded warrants to purchase ordinary shares ("Offering"), with gross proceeds to the Company expected to be approximately $81 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The Offering equates to 368,261,717 of the Company's ordinary shares at a price of $0.22 per share.

Itamar Medical Ltd. (Nasdaq: ITMR) 44.9% HIGHER; ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway, today announced that the two companies signed a definitive agreement under which ZOLL Medical will acquire all outstanding ordinary shares of Itamar Medical for a total value of approximately $538 million.

Valneva SE (NASDAQ: VALN) 39% LOWER; Valneva SE and Dynavax (NASDAQ: DVAX) today announced that they have received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this.

Leap Therapeutics, Inc. (Nasdaq: LPTX) 32% HIGHER; announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress, being held virtually on September 16-21, 2021. The Company will host a conference call on Friday, September 17, 2021 to discuss preliminary results from the study.

BELLUS Health Inc. (Nasdaq: BLU) 22% HIGHER; announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).

Dynavax (NASDAQ: DVAX) 10% LOWER; Valneva SE (NASDAQ: VALN) and Dynavax (NASDAQ: DVAX) today announced that they have received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its COVID-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the Company is in breach of its obligations under the Supply Agreement, but the Company strenuously denies this.

Leslies, Inc. (Nasdaq: LESL) 3.6% LOWER; announced that certain of the Companys stockholders (the Selling Stockholders), intend to offer for sale in an underwritten secondary offering 13,000,000 shares of the Companys common stock

Virgin Galactic Holdings, Inc. (NYSE: SPCE) 2.6% LOWER; announced an update regarding the timing of its next test flight Unity 23 with the Italian Air Force.

Lyft (NASDAQ: LYFT) 1.8% HIGHER; Goldman Sachs initiates coverage with a Buy rating and a price target of $64.00.

Academy Sports and Outdoors, Inc. (NASDAQ: ASO) 1.4% LOWER; announced that certain of its stockholders that are affiliates of Kohlberg Kravis Roberts & Co. L.P. (the Selling Stockholders) intend to offer for sale in an underwritten secondary offering 18,645,602 shares of common stock of Academy

CrowdStrike Holdings (NASDAQ: CRWD) 1.3% LOWER; Goldman Sachs downgraded from Buy to Neutral with a price target of $305.00.

You May Also Be Interested In

• Chargepoint (CHPT), EVgo (EVGO) sink as GM teams with Tesla on EV charging
• Waterdrop Inc. (WDH) Announces Proposed Acquisition of Shenzhen Cunzhen Qiushi Technology
• Viant Technology Inc. (DSP) on watch on merger rumors